Previously doing business as Structural Bioinformatics Inc, a start-up using software to convert gene sequences into three-dimensional protein structures and, at the time, 10 percent owned by Texas Biotechnology - a cardiovascular therapeutics firm. in 2003, Structural BioInformatics and GeneFormatics - both working in structure-driven drug discovery - merged to become Cengent. Two years later in April 2005. Cengent was acquired by Inncardio (OTCBB:INDO), a developer of treatments and therapies targeted at cardiovascular-related diseases. Cengent Therapeutics had functioned as a structure-guided drug discovery company utilizing integrated, proprietary computational and experimental lab technologies to accelerate and optimize the drug discovery process. The firm utilized integrated, proprietary computational and experimental lab technologies to accelerate and optimize the drug discovery process. The company currently has pre-clinical programs in obesity/diabetes, anti-infectives, oncology, and inflammation. In addition to its internal pipeline, the company has applied its technologies to advance the drug discovery programs of external collaborators. The company's technologies include: Genes To Leads® to accelerate and validate lead discovery; Structure Determination Services including augmented homology modeling, X-ray crystallography, and nuclear magnetic resonance (NMR) spectroscopy; StructureBank®, a database for the comparative analysis of protein targets and anti-targets; Proteome Analysis, a suite of technologies providing target identification and function information; and BioprospectorTM for data-mining and pattern recognition. Finally, in JUn 2006, Metabasis Therapeutics -- developing small-molecules to treat liver diseases and metabolic disorders linked to liver pathways --- acquired assets from Inncardio's Cengent Therapeutics (developing therapeutics for diabetes) that are related to its PTP-1B (protein tyrosine phosphatase-1B) program for metabolic diseases such as diabetes.
